

Sharon Ruth Lewin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2552916/sharon-ruth-lewin-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

320
papers

18,836
citations

66
h-index

128
g-index

346
ext. papers

22,079
ext. citations

8
avg, IF

6.79
L-index

#	Paper	IF	Citations
320	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.. <i>Science Translational Medicine</i> , 2022 , 14, eabl3836	17.5	6
319	Immune checkpoint blockade in HIV.. <i>EBioMedicine</i> , 2022 , 76, 103840	8.8	1
318	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.. <i>Journal of the International AIDS Society</i> , 2022 , 25, e25882	5.4	2
317	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022 , 36, 75-82	3.5	2
316	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 855290	5.9	0
315	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2021 ,	8	3
314	Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue. <i>Journal of Immunological Methods</i> , 2021 , 113198	2.5	1
313	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021 ,	50.5	16
312	Cell-associated HIV RNA has a Circadian Cycle in Males Living with HIV on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021 ,	7	3
311	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. <i>Journal of Virus Eradication</i> , 2021 , 7, 100032	2.8	1
310	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021 , 65, 103241	8.8	11
309	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021 , 2, 100208	18	46
308	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021 , 65, 103252	8.8	5
307	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1973-e1981	11.6	11
306	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , 2021 , 35, 1631-1636	3.5	2
305	Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 9, 100115	5	12
304	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab239	1	8

303	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. <i>Frontiers in Genetics</i> , 2021 , 12, 680725	4.5	2
302	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. <i>Nature Communications</i> , 2021 , 12, 4270	17.4	13
301	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021 , 12, 4450	17.4	10
300	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021 , 72, 1141-1146	11.6	0
299	The case for an HIV cure and how to get there. <i>Lancet HIV,the</i> , 2021 , 8, e51-e58	7.8	18
298	Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2021 , 39, 129-135	5.4	3
297	T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design. <i>ACS Nano</i> , 2021 , 15, 3736-3753	16.7	17
296	Multi-stakeholder consensus on a target product profile for an HIV cure. <i>Lancet HIV,the</i> , 2021 , 8, e42-e50	7.8	14
295	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. <i>PLoS Pathogens</i> , 2021 , 17, e1009214	7.6	14
294	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2021 ,	5.3	2
293	CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. <i>Journal of Virology</i> , 2020 , 94,	6.6	11
292	Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa115	1	5
291	A cure for HIV: how would we know?. <i>Lancet HIV,the</i> , 2020 , 7, e304-e306	7.8	3
290	Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents. <i>European Journal of Medicinal Chemistry</i> , 2020 , 195, 112254	6.8	1
289	Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. <i>Nature Medicine</i> , 2020 , 26, 453-455	50.5	683
288	The significance and expectations of HIV cure research among people living with HIV in Australia. <i>PLoS ONE</i> , 2020 , 15, e0229733	3.7	10
287	Combination Immune Checkpoint Blockade to Reverse HIV Latency. <i>Journal of Immunology</i> , 2020 , 204, 1242-1254	5.3	16
286	Kick and kill for HIV latency. <i>Lancet, The</i> , 2020 , 395, 844-846	40	6

285	Diverse effects of interferon alpha on the establishment and reversal of HIV latency. <i>PLoS Pathogens</i> , 2020 , 16, e1008151	7.6	18
284	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2845-2858	15.9	16
283	Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, 527-533	3.1	4
282	Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection. <i>Nucleic Acids Research</i> , 2020 , 48, 2643-2660	20.1	9
281	Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Global Challenge Needing More Research. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2807-2809	11.6	0
280	Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 744-755	7	26
279	Leveraging the advances in HIV for COVID-19. <i>Lancet, The</i> , 2020 , 396, 943-944	40	3
278	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020 , 6, 100004	2.8	6
277	Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. <i>AIDS Research and Therapy</i> , 2020 , 17, 65	3	3
276	Longitudinal analysis of subtype C envelope tropism for memory CD4 T cell subsets over the first 3 years of untreated HIV-1 infection. <i>Retrovirology</i> , 2020 , 17, 24	3.6	1
275	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1280-1288	7	42
274	Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection. <i>PLoS Pathogens</i> , 2020 , 16, e1008744	7.6	10
273	Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 260-267	1.6	11
272	Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. <i>Medical Journal of Australia</i> , 2020 , 212, 459-462	4	201
271	2018 international meeting of the Global Virus Network. <i>Antiviral Research</i> , 2019 , 163, 140-148	10.8	7
270	TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection. <i>Journal of Immunology</i> , 2019 , 203, 718-724	5.3	4
269	Between a shock and a hard place: challenges and developments in HIV latency reversal. <i>Current Opinion in Virology</i> , 2019 , 38, 1-9	7.5	31
268	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of versus Models. <i>Journal of Virology</i> , 2019 , 93,	6.6	2

267	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019 , 93,	6.6	9
266	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 5148-5175	8.3	6
265	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 692-702	6.1	18
264	Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019 , 219, 420-428	7	17
263	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 T cells from ART-suppressed individuals. <i>Nature Communications</i> , 2019 , 10, 814	17.4	91
262	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019 , 5, 167-173	2.8	4
261	Limitations of dual-fluorescent HIV reporter viruses in a model of pre-activation latency. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25425	5.4	5
260	Tesamorelin, liver fat, and NAFLD in the setting of HIV. <i>Lancet HIV,the</i> , 2019 , 6, e808-e809	7.8	2
259	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019 , 33, 773-791	3.5	18
258	Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 596-604	3.1	5
257	HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal. <i>Aids</i> , 2019 , 33, 199-209	3.5	2
256	Functional cure of HIV: the scale of the challenge. <i>Nature Reviews Immunology</i> , 2019 , 19, 45-54	36.5	54
255	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1084-1094	7	38
254	PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 1-6	3.1	10
253	Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 607-620	1.6	3
252	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV,the</i> , 2018 , 5, e221-e230	7.8	19
251	The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed. <i>Journal of Virology</i> , 2018 , 92,	6.6	21
250	Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. <i>Cell Host and Microbe</i> , 2018 , 23, 14-26	23.4	186

249	Immune Monitoring for CMV in Transplantation. <i>Current Infectious Disease Reports</i> , 2018 , 20, 4	3.9	33
248	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018 , 18, 91-104	36.5	242
247	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. <i>Lancet, The</i> , 2018 , 392, 312-358	4 ⁰	135
246	Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4 T Cells. <i>Journal of Immunology</i> , 2018 , 201, 1468-1477	5.3	12
245	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. <i>Aids</i> , 2018 , 32, 1491-1497	3.5	92
244	Barriers and strategies to achieve a cure for HIV. <i>Lancet HIV,the</i> , 2018 , 5, e317-e328	7.8	58
243	HIV integration sites and implications for maintenance of the reservoir. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 152-159	4.2	15
242	Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. <i>Aids</i> , 2018 , 32, 2119-2128	3.5	14
241	Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals. <i>Scientific Reports</i> , 2018 , 8, 14277	4.9	32
240	HIV latency reversing agents act through Tat post translational modifications. <i>Retrovirology</i> , 2018 , 15, 36	3.6	18
239	Perceptions of HIV cure research among people living with HIV in Australia. <i>PLoS ONE</i> , 2018 , 13, e0202647	4.7	25
238	Australian health professionals statement on climate change and health. <i>Lancet, The</i> , 2018 , 392, 2169-2170	1.7	3
237	HIV integration sites in latently infected cell lines: evidence of ongoing replication. <i>Retrovirology</i> , 2017 , 14, 2	3.6	37
236	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , 2017 , 91,	6.6	15
235	Ethics and hepatitis B cure research. <i>Gut</i> , 2017 , 66, 389-392	19.2	10
234	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1137-1141	3.5	9
233	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 328-337	3.1	21
232	Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1344-1346	3.5	10

231	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1684-1694	7	42
230	Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study. <i>Sexual Health</i> , 2017 , 14, 238-243	2	
229	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017 , 215, 911-919	7	51
228	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 96-104	4.2	16
227	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017 , 31, 1839-1845	3.5	6
226	Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017 , 91,	6.6	9
225	Is Australia prepared for the next pandemic?. <i>Medical Journal of Australia</i> , 2017 , 206, 284-286	4	1
224	Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 1220-1235	1.6	8
223	Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection. <i>FEBS Letters</i> , 2017 , 591, 3319-3332	3.8	41
222	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1961-1967	4.7	36
221	HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. <i>Aids</i> , 2017 , 31, 2035-2052	3.5	116
220	Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. <i>Nature Communications</i> , 2017 , 8, 69	17.4	75
219	Plasma But Not Cerebrospinal Fluid Interleukin 7 and Interleukin 5 Levels Pre-Antiretroviral Therapy Commencement Predict Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1551-1559	11.6	15
218	HIV cure research: print and online media reporting in Australia. <i>Journal of Virus Eradication</i> , 2017 , 3, 229-235	2.8	3
217	Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx032	1	8
216	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2017 , 8, 1506	8.4	8
215	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. <i>Pathogens and Immunity</i> , 2017 , 2, 310-334	4.9	7
214	Major health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1393-1403	3.5	22

213	Developing research priorities for Australia's response to infectious disease emergencies. <i>Communicable Diseases Intelligence</i> , 2017 , 41, E1-E3		
212	CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies. <i>Molecular Psychiatry</i> , 2016 , 21, 574-84	15.1	24
211	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw189	1	59
210	HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF- κ B. <i>Retrovirology</i> , 2016 , 13, 49	3.6	20
209	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016 , 7, 12731	17.4	56
208	Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy. <i>Medicine (United States)</i> , 2016 , 95, e4477	1.8	4
207	Immunity in young adult survivors of childhood leukemia is similar to the elderly rather than age-matched controls: Role of cytomegalovirus. <i>European Journal of Immunology</i> , 2016 , 46, 1715-26	6.1	15
206	Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016 , 30, 2159-68	3.5	7
205	Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw035	1	13
204	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016 , 214, 73-9	7	8
203	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV, the</i> , 2016 , 3, e8-10	7.8	17
202	Paediatric HIV infection: the potential for cure. <i>Nature Reviews Immunology</i> , 2016 , 16, 259-71	36.5	70
201	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. <i>BMC Infectious Diseases</i> , 2016 , 16, 114	4	10
200	Voices of biotech. <i>Nature Biotechnology</i> , 2016 , 34, 270-5	44.5	3
199	Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells. <i>Journal of NeuroVirology</i> , 2016 , 22, 455-63	3.9	22
198	Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro. <i>PLoS ONE</i> , 2016 , 11, e0158778	3.7	6
197	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. <i>PLoS ONE</i> , 2016 , 11, e0160192	3.7	22
196	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , 2016 , 12, e1005740	7.6	16

195	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016 , 12, e1005761	7.6	232
194	Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes. <i>Current Topics in Medicinal Chemistry</i> , 2016 , 16, 1091-106	3	6
193	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?. <i>Pathogens and Immunity</i> , 2016 , 1, 154-164	4.9	28
192	Sexual transmission of HIV and the law: an Australian medical consensus statement. <i>Medical Journal of Australia</i> , 2016 , 205, 409-412	4	6
191	Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. <i>PLoS ONE</i> , 2016 , 11, e0166549	3.7	6
190	Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. <i>Aids</i> , 2016 , 30, 1597-606	3.5	13
189	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016 , 22, 839-50	50.5	303
188	Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016 , 30, 1511-20	3.5	54
187	Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 394-401	4.2	98
186	CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. <i>Nature Immunology</i> , 2016 , 17, 1187-96	19.1	267
185	The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals. <i>Journal of Translational Medicine</i> , 2015 , 13, 30	8.5	8
184	Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. <i>Aids</i> , 2015 , 29, 504-6	3.5	93
183	Experiences and expectations of participants completing an HIV cure focused clinical trial. <i>Aids</i> , 2015 , 29, 248-50	3.5	24
182	The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells. <i>Retrovirology</i> , 2015 , 12, 76	3.6	22
181	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015 , 11, e1005000	7.6	73
180	Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. <i>PLoS Pathogens</i> , 2015 , 11, e1005237	7.6	38
179	Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 35-42	4.2	41
178	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. <i>Lancet HIV,the</i> , 2015 , 2, e520-9	7.8	159

177	Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. <i>Gut</i> , 2015 , 64, 1810-5	19.2	65
176	Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 947-54	2	3
175	Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014 , 26, 559-66	2.2	2
174	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV,the</i> , 2014 , 1, e13-21	7.8	421
173	HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. <i>Journal of Leukocyte Biology</i> , 2014 , 95, 71-81	6.5	23
172	Towards a cure for HIV--are we making progress?. <i>Lancet, The</i> , 2014 , 384, 209-11	4.0	18
171	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet, The</i> , 2014 , 384, 258-71	4.0	469
170	CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy. <i>Antiviral Therapy</i> , 2014 , 19, 429-33	1.6	3
169	Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. <i>PLoS ONE</i> , 2014 , 9, e99971	3.7	36
168	No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial. <i>PLoS ONE</i> , 2014 , 9, e109718	3.7	11
167	Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. <i>PLoS ONE</i> , 2014 , 9, e113341	3.7	17
166	Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study. <i>International Journal of Infectious Diseases</i> , 2014 , 28, 35-40	10.5	14
165	Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. <i>Immunology and Cell Biology</i> , 2014 , 92, 133-8	5	51
164	Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 476-9	1.6	8
163	Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2014 , 10, e1004473	7.6	358
162	Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. <i>Aids</i> , 2014 , 28, 297-309	3.5	106
161	Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. <i>Aids</i> , 2014 , 28, 657-66	3.5	18
160	Entry of HIV in primary human resting CD4(+) T cells pretreated with the chemokine CCL19. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 207-8	1.6	3

159	Ebola and HIV: managing febrile times. <i>Lancet HIV,the</i> , 2014 , 1, e101-2	7.8	
158	Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2014 , 210, 745-51	7	23
157	Comparison of Etests and Vitek 2 \square to broth microdilution for the susceptibility testing of <i>Cryptococcus neoformans</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 80, 294-8	2.9	12
156	Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy. <i>Antiviral Therapy</i> , 2014 , 19, 41-9	1.6	5
155	Challenges, progress and strategies in the search for a cure for HIV. <i>Microbiology Australia</i> , 2014 , 35, 72	0.8	
154	A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. <i>Retrovirology</i> , 2013 , 10, 43	3.6	50
153	The end of AIDS: HIV infection as a chronic disease. <i>Lancet, The</i> , 2013 , 382, 1525-33	40	1063
152	Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. <i>AIDS and Behavior</i> , 2013 , 17, 2253-9	4.3	15
151	A cure for HIV: where we've been, and where we're headed. <i>Lancet, The</i> , 2013 , 381, 2057-8	40	6
150	The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. <i>Virology</i> , 2013 , 442, 51-8	3.6	20
149	The search for an HIV cure: tackling latent infection. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 614-21	25.5	51
148	Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. <i>European Journal of Immunology</i> , 2013 , 43, 595-605	6.1	25
147	Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 993-1001	4.4	149
146	HIV and co-infections. <i>Immunological Reviews</i> , 2013 , 254, 114-42	11.3	81
145	Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1157-65	7	89
144	Persistent immune activation in chronic HIV infection: do any interventions work?. <i>Aids</i> , 2013 , 27, 1199-208	39.8	68
143	Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfecting with HIV and hepatitis viruses. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1379-88	7	35
142	Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. <i>PLoS Pathogens</i> , 2013 , 9, e1003799	7.6	50

141	An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. <i>PLoS Pathogens</i> , 2013 , 9, e1003834	7.6	283
140	Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfectd with HIV and hepatitis B virus. <i>Clinical Infectious Diseases</i> , 2013 , 56, e87-94	11.6	55
139	Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1604-12	7	57
138	Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN- γ responses before antiretroviral therapy but not higher T-cell responses during therapy. <i>Journal of Infectious Diseases</i> , 2013 , 208, 898-906	7	43
137	Identification of lineage relationships and novel markers of blood and skin human dendritic cells. <i>Journal of Immunology</i> , 2013 , 190, 66-79	5.3	74
136	Altering cell death pathways as an approach to cure HIV infection. <i>Cell Death and Disease</i> , 2013 , 4, e718	9.8	55
135	Is specific HIV eradication from the brain possible or needed?. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 403-9	5.4	12
134	Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. <i>Aids</i> , 2013 , 27, 2089-99	3.5	79
133	Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. <i>Aids</i> , 2013 , 27, 2853-62	3.5	51
132	Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfectd individuals. <i>PLoS ONE</i> , 2013 , 8, e61297	3.7	32
131	Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfectd subjects initiating HBV-active antiretroviral therapy in Thailand. <i>AIDS Research and Therapy</i> , 2012 , 9, 6	3	22
130	A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. <i>Nucleic Acids Research</i> , 2012 , 40, e113	20.1	8
129	HIV persistence: chemokines and their signalling pathways. <i>Cytokine and Growth Factor Reviews</i> , 2012 , 23, 151-7	17.9	12
128	Circulating heat shock protein 60 levels are elevated in HIV patients and are reduced by anti-retroviral therapy. <i>PLoS ONE</i> , 2012 , 7, e45291	3.7	14
127	Early experience with antimicrobial stewardship ward rounds at a tertiary referral hospital. <i>Medical Journal of Australia</i> , 2012 , 196, 34-5	4	6
126	Human immunodeficiency virus infection and the liver. <i>World Journal of Hepatology</i> , 2012 , 4, 91-8	3.4	43
125	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012 , 12, 607-14	36.5	414
124	HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. <i>Journal of Medical Virology</i> , 2012 , 84, 993-1001	19.7	10

123	In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. <i>Journal of Medical Virology</i> , 2012 , 84, 1166-76	19.7	8
122	HDAC inhibitors in HIV. <i>Immunology and Cell Biology</i> , 2012 , 90, 47-54	5	99
121	HIV reservoirs and strategies for eradication. <i>Current HIV/AIDS Reports</i> , 2012 , 9, 5-15	5.9	48
120	The role of SNPs in the chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. <i>Genes and Immunity</i> , 2012 , 13, 83-93	4.4	22
119	Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. <i>Journal of Immunology</i> , 2012 , 189, 1491-9	5.3	85
118	HIV Infection and TLR Signalling in the Liver. <i>Gastroenterology Research and Practice</i> , 2012 , 2012, 473925		8
117	Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. <i>Journal of Virology</i> , 2012 , 86, 1181-92	6.6	34
116	Chronic hepatitis B infection and pregnancy. <i>Obstetrical and Gynecological Survey</i> , 2012 , 67, 37-44	2.4	23
115	Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. <i>Aids</i> , 2011 , 25, 1379-83	3.5	11
114	Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. <i>Aids</i> , 2011 , 25, 197-205	3.5	36
113	The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player. <i>Clinical Immunology</i> , 2011 , 141, 253-67	9	25
112	Early events of HIV-1 infection: can signaling be the next therapeutic target?. <i>Journal of NeuroImmune Pharmacology</i> , 2011 , 6, 269-83	6.9	8
111	Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro. <i>Retrovirology</i> , 2011 , 8, 43	3.6	21
110	Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. <i>Retrovirology</i> , 2011 , 8, 80	3.6	74
109	HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. <i>Retrovirology</i> , 2011 , 8, 89	3.6	35
108	Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. <i>Biomarkers in Medicine</i> , 2011 , 5, 171-86	2.3	55
107	Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. <i>Journal of Neurosurgery</i> , 2011 , 114, 458-62	3.2	31
106	HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2011 , 89, 149-58	6.5	22

105	Plasma levels of soluble CD14 independently predict mortality in HIV infection. <i>Journal of Infectious Diseases</i> , 2011 , 203, 780-90	7	801
104	HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. <i>Journal of Virology</i> , 2011 , 85, 4330-42	6.6	63
103	Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1532-40	7	51
102	Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. <i>Clinical Infectious Diseases</i> , 2011 , 52, 493-506	11.6	124
101	Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 3691-3	9.7	35
100	CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1927-35	7	84
99	Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. <i>PLoS ONE</i> , 2011 , 6, e19968	3.7	73
98	Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. <i>PLoS ONE</i> , 2011 , 6, e20713	3.7	26
97	Splenectomy associated changes in IgM memory B cells in an adult spleen registry cohort. <i>PLoS ONE</i> , 2011 , 6, e23164	3.7	71
96	Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. <i>PLoS ONE</i> , 2011 , 6, e26482	3.7	9
95	Both CD31(+) and CD31? naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1738-48	7	88
94	No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. <i>Journal of Virology</i> , 2010 , 84, 2657-65	6.6	15
93	Preliminary assessment of Treponema pallidum-specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients. <i>International Journal of STD and AIDS</i> , 2010 , 21, 758-64	1.4	5
92	Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. <i>Journal of Virology</i> , 2010 , 84, 5860-7	6.6	42
91	Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor and microbial translocation. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1254-64	7	97
90	Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 16934-9	11.5	174
89	Australasian HIV/AIDS Conference 2009. <i>HIV Therapy</i> , 2010 , 4, 9-11		
88	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. <i>Antiviral Therapy</i> , 2010 , 15, 917-22	1.6	21

87	A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. <i>Journal of Virological Methods</i> , 2010 , 165, 90-6	2.6	9
86	Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders. <i>Clinical Immunology</i> , 2010 , 137, 199-208	9	4
85	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. <i>Virology</i> , 2010 , 405, 539-47	3.6	23
84	Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. <i>Hepatology</i> , 2010 , 51, 1933-44	11.2	324
83	Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study. <i>PLoS ONE</i> , 2010 , 5, e9643	3.7	13
82	Fatal acute varicella-zoster virus hemorrhagic meningomyelitis with necrotizing vasculitis in an HIV-infected patient. <i>Clinical Infectious Diseases</i> , 2009 , 48, 372-3	11.6	15
81	Immune restoration diseases reflect diverse immunopathological mechanisms. <i>Clinical Microbiology Reviews</i> , 2009 , 22, 651-63	34	52
80	Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. <i>Journal of Leukocyte Biology</i> , 2009 , 85, 1027-35	6.5	32
79	The "work" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009 , 21, 1230-7	2.2	14
78	Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. <i>Journal of Virology</i> , 2009 , 83, 7649-58	6.6	33
77	Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2009 , 199, 974-81	7	65
76	Differential dynamics of donor DC and non-DC peripheral blood mononuclear cell microchimerism in lung transplantation. <i>Clinical Immunology</i> , 2009 , 133, 179-83	9	2
75	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfecting individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. <i>Hepatology</i> , 2009 , 49, 1113-21	11.2	18
74	Antenatal screening practice for infectious diseases by general practitioners in Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009 , 49, 39-44	1.7	10
73	Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. <i>HIV Medicine</i> , 2009 , 10, 229-35	2.7	31
72	The novel histone deacetylase inhibitors metacept-1 and metacept-3 potentially increase HIV-1 transcription in latently infected cells. <i>Aids</i> , 2009 , 23, 2047-50	3.5	28
71	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfecting individuals. <i>Aids</i> , 2009 , 23, 1707-15	3.5	43
70	Future directions in the treatment of HIV-HBV coinfection. <i>HIV Therapy</i> , 2009 , 3, 405-415		7

69	Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. <i>Medical Journal of Australia</i> , 2009 , 190, 220-221	4	
68	The pathogenesis of liver disease in the setting of HIV/Hepatitis B virus coinfection. <i>Antiviral Therapy</i> , 2009 , 14, 155-164	1.6	11
67	Human thymic dendritic cells: regulators of T cell development in health and HIV-1 infection. <i>Clinical Immunology</i> , 2008 , 126, 1-12	9	9
66	Corneal stromal bed quality obtained with mechanical microkeratome and femtosecond laser. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 27, 746; author reply 746-7	3.1	33
65	Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir. <i>Current HIV Research</i> , 2008 , 6, 272-5	1.3	1
64	Sexually transmissible infection and HIV management among men who have sex with men with and without HIV: survey of medical practitioners who are members of the Australasian Society for HIV Medicine. <i>Sexual Health</i> , 2008 , 5, 155-9	2	1
63	Hepatitis virus immune restoration disease of the liver. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 446-52	4.2	12
62	The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. <i>Aids</i> , 2008 , 22, 947-55	3.5	36
61	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. <i>Hepatology</i> , 2008 , 48, 741-9	11.2	18
60	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. <i>Hepatology</i> , 2008 , 48, 1062-9	11.2	104
59	Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. <i>Sexual Health</i> , 2008 , 5, 61-7	2	12
58	Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 47, 140-47	3.1	28
57	A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. <i>Antiviral Therapy</i> , 2008 , 13, 161-75	1.6	38
56	A Systematic Review of T-cell Epitopes in Hepatitis B Virus: Identification, Genotypic Variation and Relevance to Antiviral Therapeutics. <i>Antiviral Therapy</i> , 2008 , 13, 161-176	1.6	69
55	Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. <i>Retrovirology</i> , 2007 , 4, 66	3.6	51
54	The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. <i>Retrovirology</i> , 2007 , 4, 7	3.6	30
53	Ten years of highly active antiretroviral therapy for HIV infection. <i>Medical Journal of Australia</i> , 2007 , 186, 146-51	4	72
52	Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. <i>Hepatology</i> , 2007 , 45, 102-10	11.2	267

51	The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. <i>Hepatology</i> , 2007 , 46, 1332-40	11.2	40
50	Immunopathogenesis of hepatitis B virus infection. <i>Immunology and Cell Biology</i> , 2007 , 85, 16-23	5	146
49	Immune recovery uveitis in an HIV-negative individual. <i>Clinical and Experimental Ophthalmology</i> , 2007 , 35, 189-90	2.4	7
48	Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. <i>Clinical Immunology</i> , 2007 , 124, 200-6	9	13
47	Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 278-278	9.7	78
46	The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. <i>Journal of Immunology</i> , 2007 , 178, 6581-9	5.3	259
45	Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. <i>Aids</i> , 2007 , 21, 1701-10	3.5	31
44	Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. <i>Journal of Virology</i> , 2007 , 81, 2297-306	6.6	34
43	Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples. <i>Vaccine Journal</i> , 2007 , 14, 52-9		17
42	CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. <i>Blood</i> , 2007 , 110, 4161-4	2.2	183
41	What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians. <i>Aids</i> , 2007 , 21, 1601-6	3.5	6
40	The Sydney Declaration: a call to scale up research. <i>Lancet, The</i> , 2007 , 370, 7-8	40	15
39	Immunopathogenesis: role of innate and adaptive immune responses. <i>Seminars in Liver Disease</i> , 2006 , 26, 104-15	7.3	33
38	Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 2983-7	9.7	10
37	Thymic function in severely immunodeficient HIV type 1-infected patients receiving stable and effective antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 163-70	1.6	25
36	HIV research in Australia: linking basic research findings with clinical and public health outcomes. <i>Retrovirology</i> , 2006 , 3, 86	3.6	
35	Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. <i>Aids</i> , 2006 , 20, 863-70	3.5	133
34	Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 140-8	3.1	17

33	Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. <i>Virology</i> , 2005 , 337, 384-98	3.6	100
32	Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. <i>Journal of Virology</i> , 2005 , 79, 3038-51	6.6	70
31	Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3809-12	9.7	21
30	Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipodystrophy randomized to receive abacavir. <i>Journal of Infectious Diseases</i> , 2004 , 190, 688-92	7	36
29	A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. <i>HIV Clinical Trials</i> , 2004 , 5, 91-8		7
28	Highly reproducible transient transfections for the study of hepatitis B virus replication based on an internal GFP reporter system. <i>Journal of Virological Methods</i> , 2004 , 121, 65-72	2.6	2
27	Graves Disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 157-62	1.6	45
26	Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient. <i>Aids</i> , 2004 , 18, 1734-7	3.5	6
25	Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. <i>Aids</i> , 2003 , 17, 1649-57	3.5	56
24	Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. <i>Immunology and Cell Biology</i> , 2003 , 81, 487-95	5	74
23	HIV-1 cell entry and advances in viral entry inhibitor therapy. <i>Journal of Clinical Virology</i> , 2003 , 26, 121-32	4.5	52
22	Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. <i>Journal of Infectious Diseases</i> , 2003 , 187, 1915-23	7	22
21	A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. <i>Clinical Infectious Diseases</i> , 2003 , 37, 315-6	11.6	48
20	Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. <i>Antiviral Research</i> , 2002 , 55, 381-96	10.8	43
19	Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. <i>Virology</i> , 2002 , 299, 88-99	3.6	124
18	HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. <i>Journal of Immunology</i> , 2002 , 168, 2895-903	5.3	69
17	Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. <i>Journal of Immunology</i> , 2002 , 169, 4657-66	5.3	43
16	Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 271-7	3.1	98

15	Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. <i>Blood</i> , 2002 , 100, 159-66	2.2	99
14	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. <i>Blood</i> , 2002 , 100, 2235-2242	2.2	144
13	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. <i>Blood</i> , 2002 , 100, 2235-2242	2.2	15
12	Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. <i>Hepatology</i> , 2001 , 34, 1012-20	11.2	176
11	Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 147-59	1.6	19
10	Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. <i>Journal of Clinical Virology</i> , 2001 , 22, 241-7	14.5	61
9	Pneumocystis carinii pneumonia after cessation of secondary prophylaxis in a patient on highly active antiretroviral therapy with a CD4 cell count greater than 200/mm ³ . <i>Aids</i> , 2001 , 15, 1912-3	3.5	4
8	Age-dependent changes in T cell homeostasis and SIV load in sooty mangabeys. <i>Journal of Medical Primatology</i> , 2000 , 29, 158-65	0.7	19
7	Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. <i>Journal of Virology</i> , 2000 , 74, 1209-23	6.6	171
6	Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. <i>Journal of Experimental Medicine</i> , 1999 , 190, 725-32	16.6	302
5	Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. <i>Journal of Experimental Medicine</i> , 1999 , 189, 991-8	16.6	1218
4	Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. <i>New England Journal of Medicine</i> , 1999 , 340, 1605-13	59.2	721
3	HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. <i>Aids</i> , 1998 , 12, 719-27	3.5	60
2	Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 877-83	1.6	61
1	The role of bronchoscopy in the diagnosis and treatment of pulmonary disease in HIV-infected patients. <i>Australian and New Zealand Journal of Medicine</i> , 1995 , 25, 133-9		9